Navigation Links
Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Date:8/14/2014

REDWOOD CITY, Calif., Aug. 14, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira® in healthy subjects.  The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined, PK endpoints: maximum serum concentration (Cmax), area under the time-concentration curve from first to last time point measured (AUC0-t), and area under the time-concentration curve from first time point extrapolated to infinity (AUC0-inf), with all three geometric mean ratios fully within the 90% confidence interval from 80% to 125%.  Both agents were well tolerated and there were no differential safety findings observed between the two agents in this study.

"An essential global regulatory requirement is the completion of a clinical study directly comparing the originator and our biosimilar candidate establishing PK similarity," said Barbara Finck, M.D., Chief Medical Officer of Coherus. "We are pleased to have achieved robust results which we believe represents a significant reduction in development program risk."

"Adalimumab is a very complex molecule. Achieving this clinical milestone further validates Coherus' development platform and demonstrates our ability to advance biosimilars across our portfolio," said Denny Lanfear, President and Chief Executive Officer of Coherus.

About Coherus BioSciences, Inc.
Coherus is a late-stage clinical biologics platform company focused on the global biosimilar market.  Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development.  Coherus' commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access.  For additional information, please visit www.coherus.com.

Coherus BioSciences Contact
Beth Jimison
(650) 649-3526
bjimison@coherus.com

Logo - http://photos.prnewswire.com/prnh/20120507/SF01448LOGO


'/>"/>
SOURCE Coherus BioSciences
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Coherus anuncia início do estudo Fase 3 do CHS-0214 (Biossimilar Investigativo do Etanercept) em psoríase crônica em placas (RaPsOdy)
2. Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy)
3. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
4. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
5. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
6. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
7. Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update
8. Edison Nation Medical Announces Innovation Search To Improve Hazardous Waste Disposal in Hospitals & Healthcare Facilities
9. NW BIO ANNOUNCES PRICING OF $17.5 MILLION OFFERING OF CONVERTIBLE NOTES
10. Vermillion Announces Additions to Commercial Management Team
11. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... the development of oral drug delivery systems, announced today that ... presented by Joseph Gunnar & Co. LLC, taking ... . Nadav Kidron , CEO of Oramed, will ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/27/2016)... Mass., April 27, 2016  Hologic, Inc. (Nasdaq: ... financial results for the fiscal second quarter ended ... (EPS) of $0.24 increased 41.2%, and non-GAAP diluted ... million increased 5.8% on a reported basis, and ... "We posted another good quarter, highlighted by ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... ... , ... Dr. Robert Mondavi, one of the dentists in Torrance , ... fast-growing field as more patients are discovering the many different ways they can change ... currently available to them and which ones might work for their smiles. , ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with Ed Begley Jr., ... episode, airing third quarter 2016 via Discovery Channel. Dates and show times TBA. ... Products, located in Greenwood, Wisconsin applies product research and development and continuous technological ...
(Date:4/29/2016)... Village, CA (PRWEB) , ... April 29, 2016 ... ... Philadelphia Pet Expo to promote their animal line of probiotics, Petbiotics ™, ... see the large turnout of animal rescue groups networking for their non-profit organizations. ...
(Date:4/29/2016)... ... 2016 , ... Intellitec Solutions will be a sponsor at ... the Broward County Convention Center. The event is a chance for finance professionals ... public facility management. Intellitec Solutions will highlight their customized accounting solutions designed for ...
Breaking Medicine News(10 mins):